The transient receptor potential vanilloid (TRPV) 1 receptor, a nonselective cation channel expressed on peripheral sensory neurons and in the central nervous system, plays a key role in pain. TRPV1 receptor antagonism is a promising approach for pain management. In this report, we describe the pharmacological and functional characteristics of a structurally novel TRPV1 antagonist, (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), which has entered clinical trials. At the recombinant human TRPV1 receptor ABT-102 potently (IC 50 ϭ 5-7 nM) inhibits agonist (capsaicin, N-arachidonyl dopamine, anandamide, and proton)-evoked increases in intracellular Ca 2ϩ levels. ABT-102 also potently (IC 50 ϭ 1-16 nM) inhibits capsaicin-evoked currents in rat dorsal root ganglion (DRG) neurons and currents evoked through activation of recombinant rat TRPV1 currents by capsaicin, protons, or heat. ABT-102 is a competitive antagonist (pA 2 ϭ 8.344) of capsaicin-evoked increased intracellular Ca 2ϩ and shows high selectivity for blocking TRPV1 receptors over other TRP receptors and a range of other receptors, ion channels, and transporters. In functional studies, ABT-102 blocks capsaicin-evoked calcitonin gene-related peptide release from rat DRG neurons. Intraplantar administration of ABT-102 blocks heat-evoked firing of wide dynamic range and nociceptive-specific neurons in the spinal cord dorsal horn of the rat. This effect is enhanced in a rat model of inflammatory pain induced by administration of complete Freund's adjuvant. Therefore, ABT-102 potently blocks multiple modes of TRPV1 receptor activation and effectively attenuates downstream consequences of receptor activity. ABT-102 is a novel and selective TRPV1 antagonist with pharmacological and functional properties that support its advancement into clinical studies.
. In a recent study, both peripheral and central TRPV1 receptors have been implicated in contributing to the broad-spectrum analgesia demonstrated by TRPV1 antagonists (Cui et al., 2006) .
The TRPV1 receptor can be activated by the exogenous agonists capsaicin and resiniferatoxin, by noxious heat (Ͼ42°C), and by extracellular protons, pH Ͻ6.0 (Caterina et al., 1997; Tominaga et al., 1998) . The receptor is also activated by several endogenous substances, including the endocannabinoid anandamide and N-arachidonyl dopamine (NADA) (Smart et al., 2000; Huang et al., 2002) , and by metabolites from the lipoxygenase pathway, such as 12-hydroperoxyeicosatetraenoic acid (Hwang et al., 2000) . These diverse stimuli not only directly activate the TRPV1 receptor but also sensitize the receptor, thereby reducing the threshold for activation by other stimuli. Inflammatory mediators, such as prostaglandins, bradykinin, and nerve growth factor, also modulate TRPV1 receptors. Acting via downstream signaling pathways that include protein kinase C (PKC), these inflammatory agents act to sensitize the receptor (Bonnington and McNaughton, 2003; Moriyama et al., 2005; Sikand and Premkumar, 2007) . For example, phosphorylation of the TRPV1 receptor by PKC lowers the threshold for activation such that it can be activated at normal body temperature (Sikand and Premkumar, 2007) . PKC activation has been reported to contribute to chronic pain (Hua et al., 1999) . In addition to activation and sensitization of TRPV1 receptors, inflammatory stimuli also affect TRPV1 receptor expression. Up-regulation of TRPV1 receptor expression in axons of unmyelinated neurons and an increased transport of TRPV1 mRNA from the cell bodies to central (superficial laminae of the spinal cord dorsal horn) and peripheral terminals (Carlton and Coggeshall, 2001; Tohda et al., 2001 ) are both associated with inflammatory pain.
TRPV1 receptor activation results in activation of nociceptive-specific (NS) and wide dynamic range (WDR) neurons in the spinal cord (Eckert et al., 2006; McGaraughty et al., 2006) . These two classes of neurons play a significant role in pain transmission. At the molecular level, TRPV1 receptor activation results in the release of neuropeptides such as calcitonin gene-related peptide (CGRP) from the peripheral and central terminals of sensory neurons (Rigoni et al., 2003) . CGRP plays a role in pain through sensitization of the central nervous system and in neurogenic inflammation and associated pain in the peripheral nervous system (Kilo et al., 1997; Bird et al., 2006) .
The search for potent and selective TRPV1 antagonists that are efficacious in animal models of chronic pain and exhibit pharmacokinetic properties suitable for clinical development has been the subject of intense research in the pharmaceutical industry in recent years (Szallasi et al., 2007) . However, many of the reported TRPV1 antagonists, although potent, have poor pharmaceutical properties, and only a fraction of them have advanced beyond preclinical studies (Szallasi et al., 2007) . In addition, an efficacious TRPV1 antagonist may also need to demonstrate the ability to potently inhibit TRPV1 receptor activation by the multiple stimuli that could directly or indirectly enhance the activity of this polymodal receptor. In the present study, we describe a novel TRPV1 antagonist, ABT-102, which blocks TRPV1 channel opening by multiple stimuli, CGRP release from dorsal root ganglion (DRG) neurons and neuronal firing in the rat spinal cord. Taken together, these properties support the advancement of ABT-102 into clinical trials.
Materials and Methods

Materials.
Cell culture media and fetal bovine serum (FBS) were obtained from Sigma-Aldrich (St. Louis, MO). G-418 (Geneticin) sulfate was obtained from Calbiochem (San Diego, CA). Dulbecco's phosphate-buffered saline (D-PBS), pH 7.4 (with calcium, magnesium and 1 mg/ml D-glucose) was obtained from Invitrogen (Carlsbad, CA). Fluo-4 AM was purchased from Tef Labs (Austin, TX). NADA was purchased from Tocris Cookson Inc. (Ellisville, MO). ABT-102, A-425619 (El Kouhen et al., 2005) , AMG 6880 (Gavva et al., 2005a) , AMG 517 (Doherty et al., 2007) , BCTC (Valenzano et al., 2003) , SB-452533 (Rami et al., 2004) , and agonist 6 (Casillas et al., 2006) were synthesized at Abbott Laboratories (Abbott Park, IL). All other chemicals were obtained from Sigma-Aldrich, unless otherwise indicated.
Animals. Male Sprague-Dawley rats (200 -400 g) (Charles River Laboratories, Inc., Wilmington, MA) were used in experiments (specific size ranges are described below) and were housed in a temperature-controlled room with a 12-h day/night cycle. Food and water were available ad libitum. All animal handling and experimental protocols were approved by Abbott's Institutional Animal Care and Use Committee and conducted in accordance with the ethical principles for pain-related animal research of the American Pain Society.
Assay of TRPV1 Receptor-Mediated Changes in Intracellular Ca 2؉ Levels. Cloning and stable expression of the human TRPV1 receptor in HEK 293 cells and measurement of TRPV1-mediated elevation of intracellular calcium levels using the fluorescent calcium chelating dye Fluo-4, was as described previously (El Kouhen et al., 2005) . The TRPV1 receptor cDNA sequence expressed in these cells corresponds to accession number AL136801. Assay of the effect of compounds on TRPV1 receptor activity stimulated by capsaicin, anandamide, NADA, or protons or under conditions of phorbol ester-mediated sensitization was also as described previously (El Kouhen et al., 2005) . In washout studies, cells were washed in 250 l of D-PBS multiple times before treatment with capsaicin. In all of these studies, changes in fluorescence were recorded over time in a fluorometric imaging plate reader (FLIPR) ( EX ϭ 488 nm; EM ϭ 540 nm; Molecular Devices, Sunnyvale, CA). Antagonists were tested at 11 concentrations (indicated on each graph). The peak increase in fluorescence over baseline (relative fluorescence units) was calculated and expressed as a percentage of the maximal agonist response (in the absence of the antagonist). EC 50 and IC 50 values were calculated from curve fits of the concentration-effect data using a four-parameter logistic Hill equation (GraphPad Prism; GraphPad Software Inc., San Diego, CA). Significant differences were calculated by unpaired, two-tailed Student's t tests. IC 50 values at the human TRPV1 receptor obtained in this study, using TRPV1 stably expressed in HEK 293 cells (see Results), are very similar to those we have observed using human TRPV1 stably expressed in 1321N cells (Gomtsyan et al., 2008) .
Transient Expression of Other TRP Receptors and Assay of TRP Receptor-Mediated Increases in Intracellular Ca
2؉ Levels. Human recombinant TRP receptors with cDNA sequences corresponding to the following accession numbers were used in assays to assess selectivity: TRPV3 (NM_145068), TRPV4 (NM_021625), transient receptor potential melastatin (TRPM) 8 (NM_024080), and transient receptor potential A-1 (TRPA1) (NM_007332). TRP channels were transiently expressed and assayed for responses to agonist-induced Ca 2ϩ flux in the absence or presence of ABT-102 using FLIPR technology. Transient expression of TRPV3, TRPV4, TRPM8, and TRPA1 channels was performed in FreeStyle HEK 293-F cells using the FreeStyle 293 expression system (Invitrogen), as described previously (Bianchi et al., 2007) .
For assay, cells were thawed and prepared as described previously (Bianchi et al., 2007) . Cells (25,000 cells/well for TRPV3 and TRPV4, 100,000 cells per well for TRPA1 and TRPM8) were then seeded into black-walled clear-bottom 96-well BioCoat poly-D-lysine assay plates (BD Biosciences, San Jose, CA) and incubated 2 to 24 h at 37°C under a humidified 5% CO 2 atmosphere in preparation for assay. Ca 2ϩ influx was measured using Fluo-4 AM loading dye (Invitrogen), as described above for TRPV1. Activators for these other TRP receptors were as follows: 62.5 M 2-aminoethoxydiphenyl borate (2-APB) (Tocris Cookson Inc.) for TRPV3, 2 M agonist 6 from WO2006029210 (Casillas et al., 2006) for TRPV4, 10 M menthol for TRPM8, and 30 M mustard oil for TRPA1.
DRG Neuronal Cultures for Electrophysiological and CGRP Release Studies. All experiments were carried out in accordance with the guidelines and the approval of the Institutional Animal Care and Use Committee. All media, antibiotics, and enzymes were obtained from Invitrogen, unless indicated.
For electrophysiological studies, DRG neurons (L 4 -L 6 ) were dissected from 200 to 300-g male Sprague-Dawley rats (Charles River Laboratories, Inc.) and placed in DMEM containing 0.3% collagenase B (Roche Diagnostics, Indianapolis, IN) for 60 min at 37°C. The collagenase was replaced with 0.25% trypsin (Invitrogen) in Ca 2ϩ / Mg 2ϩ -free D-PBS, followed by further incubation for 30 min at 37°C. After washing in fresh DMEM, neurons were dissociated by trituration using a sterile fire-polished Pasteur pipette and plated on polyethylenimine-treated 12-mm glass coverslips in 1 ml of DMEM supplemented with 10% FBS, nerve growth factor (50 ng/ml), 100 U/ml penicillin, and 100 g/ml streptomycin. Electrophysiological recordings were performed 15 to 30 h later on individual neurons.
For CGRP release studies, DRG neurons were prepared similarly to previous studies (El Kouhen et al., 2005) , with minor modifications. Seven-to eight-week-old Sprague-Dawley rats (Charles River Laboratories, Inc.) were deeply anesthetized with CO 2 and euthanized by decapitation. DRG were rapidly removed and collected in ice-cold dissection solution (DMEM containing 10% heat-inactivated horse serum plus 100 U/ml penicillin and 100 g/ml streptomycin). Isolated DRG were transferred to a tube containing 0.1% Collagenase B (Roche Diagnostics) in minimal essential medium/Ham's F12 (1:1) medium and allowed to incubate for 90 min at 37°C. After the incubation, the tissue was centrifuged at 1000 rpm (170g) for 5 min, the supernatant was removed, and the pellet was resuspended in 20 U/ml papain (Worthington Biochemicals, Freehold, NJ) plus 50 g/ml DNase IV in phosphate-buffered saline, pH 7.4, and allowed to incubate for an additional 60 min at 37°C. The tissue was then dissociated by trituration with the use of a plastic Pasteur pipette. Undisrupted tissue fragments were allowed to settle, and the supernatant was layered over Earle's balanced salt solution containing 15% FBS and centrifuged at 1000 rpm (170g) for 5 min. The resulting pellet was resuspended in minimal essential medium/Ham's F12 (1:1) medium containing 10% heat-inactivated horse serum, 4 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were plated in a 96-well poly-L-ornithine/laminin BioCoat plate (BD Biosciences) at 10,000 cells/well.
In Vitro Electrophysiology. Patch-clamp recordings using rat DRG neurons and HEK 293 cells stably expressing recombinant rat TRPV1 were performed in an extracellular recording solution, pH 7.4 (325 mOsm), consisting of: 155 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 12 mM glucose. The recombinant rat TRPV1 cDNA sequence used in this study corresponds to accession number NM_031982. For experiments using pH 5.5, MES was used in place of HEPES in the external solution. Patch pipettes composed of borosilicate glass (1B150F-3; World Precision Instruments, Inc., Sarasota, FL) were pulled and fire-polished using a DMZ-Universal micropipette puller (Zeitz Instrumente GmbH, Munich, Germany). Pipettes (2-6 M⍀) were filled with an internal solution, pH 7.3 (295 mOsm), consisting of 122.5 mM potassium aspartate, 20 mM KCl, 1 mM MgCl 2 , 10 mM EGTA, 5 mM HEPES, and 2 mM ATP⅐Mg.
Coverslips plated with cells were placed in a perfusion chamber, and bath perfusion (ϳ2 ml/min) was initiated after establishment of whole-cell recording conditions. Standard whole-cell recording techniques were employed using an Axopatch 200B amplifier (Molecular Devices). Unless otherwise noted, membrane potentials of the cells were voltage-clamped at Ϫ60 mV. Application of control bath solution through a multibarrel application device with a common 360-m polyimide tip (Cell Microcontrols, Norfolk, VA), positioned ϳ100 m from the cell, was continued throughout the recording except during drug application. Each drug reservoir was connected to solenoid Teflon or pinch valves that were controlled by a ValveLink16 system (AutoMate Scientific, San Francisco, CA). Drug application protocols were established using pCLAMP (Molecular Devices) software that controlled rapid valve switching through the ValveLink system. Drugs were applied once the amplitude of the agonist response stabilized, typically after an initial (5 min) current run down. Drugs were applied by gravity feed through the drug application device for durations described under Results. Each drug application sequence was followed by a washout period of 90 to 120 s. Capsaicin, protons (acidic pH), or heat were applied for 5 s at 2-min intervals to individual cells. For antagonist studies, ABT-102 was applied 1 min before application of agonist, except when the rate of block of capsaicin-or proton-mediated TRPV1 currents was assessed; in these studies, antagonist was added after preincubation in capsaicin or acidic solution. For all studies, a temperature-calibrated MPRE8 multitube preheater was connected to the polyimide tip and controlled by a TC2PKG temperature control system (Cell MicroControls). Unless otherwise indicated, the temperature of the solutions applied to the cells was maintained at room temperature (ϳ22°C). Any baseline currents were observed to be stable. Activation of heat-activated currents using this system was shown to exhibit biophysical (outward rectification), pharmacological (blocked by capsazepine), and kinetic properties consistent with TRPV1 channels.
Data acquisition and analysis were performed using pCLAMP 9.0. The effect of ABT-102 on TRPV1 receptor currents was assessed by measurement of the average current amplitude (compared with the agonist control) during the last second of recording, which accommodates for any desensitization that might have occurred during the recording period. Graphs were plotted and statistical analysis performed using GraphPad Prism (GraphPad Software Inc.). Agonist and antagonist concentration-response curves were fitted by a leastsquares regression to the logistic equation provided in the GraphPad software:
CGRP Release. CGRP release was measured using the protocol described by (Gavva et al., 2005b) , with minor modifications. Rat DRG were dissociated and plated onto precoated poly-L-ornithine/ Laminin BioCoat 96-well plates at a density of 10,000 cells per well and neurons cultured for 72 h before initiation of the CGRP release assay. After removing media, the neuronal cultures were rinsed once with CGRP release buffer containing 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl 2 , 3.3 mM glucose, 25 mM HEPES, 2 M phosphoramidon, and 0.1% bovine serum albumin, pH 7.4. The cultures were stimulated with 300 nM capsaicin for 20 min at room temperature to evoke CGRP release. To observe the effect of antagonist, neurons were preincubated with 90 l of different concentrations of antagonist at room temperature for 15 min followed by addition of 10 l of 3 M capsaicin for another 20 min. At the end of the incubation, 100 l of supernatant solution was analyzed using a CGRP enzyme-linked immunosorbent assay (Cayman Chemical, Ann Arbor, MI), and CGRP levels were measured according to the manufacturer's instructions.
In Vivo Electrophysiology. In vivo electrophysiology experiments were conducted as described previously (McGaraughty et al., 2006) . To induce chronic inflammatory hyperalgesia, a 150-l solution of 1:1 complete Freund's adjuvant (CFA) and PBS was injected s.c. into the plantar region of the rat's right hind paw 48 h before the experiment. In these studies, CFA-inflamed and uninjured rats ABT-102 Blocks TRPV1 and Heat-Evoked Neuronal Firing 881 at ASPET Journals on April 3, 2017 jpet.aspetjournals.org (350 -400 g) were initially anesthetized with pentobarbital (50 mg/kg i.p.). A catheter was placed into an external jugular vein, and a laminectomy was performed to remove vertebral segments T 12 to L 3 . Animals were then secured in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) supported by clamps attached to the vertebral processes on either side of the exposure site. A stable plane of anesthesia was maintained throughout the experiment by a continuous infusion of propofol at a rate of 8 to 12 mg/kg/h i.v. Body temperature was kept at approximately 37°C by placing the animals on a circulating water blanket. Platinum iridium microelectrodes (Frederick Haer, Brunswick, ME) were used to record extracellular activity of WDR or NS neurons. Spike waveforms were monitored on an oscilloscope throughout the experiment, digitized (32 points) and then stored for off-line analysis (SciWorks; Datawave Technologies, Longmont, CO) to ensure that the unit under study was unambiguously discriminated throughout the experiment. Except for five experiments in which easily distinguished neurons were simultaneously recorded on one electrode, only one cell was studied in each experiment. Thermally evoked responses of WDR and NS neurons were recorded before and after administration of ABT-102 (30 -300 nmol in 50 l) into the neuronal receptive field on the hind paw in CFA-inflamed and uninjured rats. To equate baseline levels of evoked firing between the two groups of rats (McGaraughty et al., 2006) , uninjured and CFA-treated animals received different intensities of thermal stimulation. Thus, the ipsilateral hind paw of uninjured rats was immersed in 52°C water for 10 s, and the hind paw of CFA-injected rats was immersed in 47°C water for 10 s. Statistical significance was established by using a Wilcoxon matched pairs test for comparisons with baseline firing levels, and by a Kruskal-Wallis analysis of variance followed by a Mann-Whitney U test was used for comparison across groups (p Ͻ 0.05).
Results
ABT-102 Is a Potent Antagonist at Recombinant Human and Rat TRPV1 Receptors. The ability of ABT-102 (Fig. 1A) to inhibit TRPV1 receptor activation was investigated in HEK 293 cells stably expressing the human recombinant receptor in a FLIPR-based assay of intracellular calcium levels, as described previously (El Kouhen et al., 2005) . In this assay, we have previously demonstrated (El Kouhen et al., 2005 ) that activation of human TRPV1 receptors by capsaicin, anandamide, NADA (shown in Supplemental Fig.  1A) , and protons, pH 5.5 (shown in Supplemental Fig. 1B) , leads to concentration-dependent increases in intracellular calcium levels (El Kouhen et al., 2005) . A concentration of each agonist that corresponds to the approximate EC 50 value obtained in those studies (capsaicin EC 50 ϭ 36 nM, NADA EC 50 ϭ 2870 nM, anandamide EC 50 ϭ 8650 nM, and proton EC 50 ϭ pH 5.5) was used to determine the potency of ABT-102 in this study (Fig. 1B) . ABT-102 blocked recombinant human TRPV1 activation by 50 nM capsaicin in a concentration-dependent manner, with a pIC 50 value of 8.13 Ϯ 0.04 (IC 50 ϭ 7 nM; n ϭ 11). ABT-102 also blocked recombinant human TRPV1 receptor activation by NADA (3 M), anandamide (10 M), and protons, pH 5.5, with similar potency, with IC 50 values of 4, 5, and 6 nM, respectively (Fig. 1B) . The ability of ABT-102 to block the effects of NADA or anandamide was not complete and probably reflects non-TRPV1-mediated effects of these agonists (El Kouhen et al., 2005) . The potency of ABT-102 against TRPV1 receptor activation by 50 nM capsaicin compared with the potency of other TRPV1 receptor antagonists, A-425619, AMG 6880, SB-452533, BCTC, and capsazepine, is shown in Fig. 1C . pIC 50 values obtained were 8.13 Ϯ 0.04 (IC 50 ϭ 7 nM; n ϭ 11) for ABT-102 versus 8.45 Ϯ 0.04 (IC 50 ϭ 4 nM; n ϭ 10) for A-425619, 6.90 Ϯ 0.06 (IC 50 ϭ 127 nM; n ϭ 6) for AMG 6880, 6.71 Ϯ 0.03 (IC 50 ϭ 195 nM; n ϭ 3) for SB-452533, 7.67 Ϯ 0.05 (IC 50 ϭ 21 nM; n ϭ 9) for BCTC, and 6.83 Ϯ 0.02 (IC 50 ϭ 148 nM; n ϭ 16) for capsaz- epine. The ability of ABT-102 to block TRPV1 receptor activation was reversible as indicated by the restoration of the ability of capsaicin to stimulate calcium influx after washout of the antagonist (Fig. 1D) . In addition, ABT-102, at concentrations up to 100 M, did not show any effects on human TRPV1 receptors in the absence of agonist (data not shown).
ABT-102 potently blocked recombinant rat TRPV1 receptor activation in whole-cell voltage-clamp electrophysiology assays. ABT-102 inhibited capsaicin-induced currents ( Fig.  2A) , with a pIC 50 value of 9.01 Ϯ 0.10 (IC 50 ϭ 1 nM; n ϭ 3) (Fig. 2B) . ABT-102 also blocked proton (pH 5.5)-mediated currents at rat TRPV1 receptors (Fig. 2C) , with a pIC 50 value of 7.78 Ϯ 0.12 (IC 50 ϭ 16 nM; n ϭ 5) (Fig. 2D) . At 100 nM, ABT-102 completely blocked heat (50°C)-activated rat TRPV1 currents to background levels (n ϭ 4) (Fig. 3A) . In these cells, a small background non-TRPV1-mediated heatevoked current is apparent (Fig. 3A) . As shown in Fig. 3B , ABT-102 clearly reduced heat-evoked TRPV1-mediated currents in a concentration-dependent manner and at 100 nM reduced the TRPV1 receptor-mediated current to background levels. Thus, ABT-102 potently blocks recombinant human and rat TRPV1 receptors activated by different stimuli.
ABT-102 Is a Potent Antagonist at the Native Rat TRPV1 Receptor. ABT-102 produced a concentration-dependent inhibition of currents elicited by 1 M capsaicin in small-diameter (20 -30 m) DRG neurons (Fig. 4A) , with a pIC 50 value of 8.24 Ϯ 0.08 (IC 50 ϭ 6 nM; n ϭ 8) (Fig. 4B) . This value agrees well with that obtained at the recombinant rat TRPV1 receptor, using both electrophysiology and calcium influx assays, and confirms the high potency of ABT-102 at endogenously expressed TRPV1 in a native system.
ABT-102 Is a Highly Selective TRPV1 Antagonist. The selectivity of ABT-102 was evaluated versus other TRP receptors. EC 50 values were determined for the agonist for each (Fig. 5A) . The concentration of each agonist that corresponded to its EC 50 value at its respective receptor was then used to assess potency of ABT-102 at these receptors. As shown in Fig. 5B , ABT-102 was highly selective as an antagonist of TRPV1 versus other TRP receptors, with IC 50 values of Ͼ100 M for TRPV3, Ͼ100 M for TRPV4, Ͼ30 M for TRPM8, and Ͼ30 M for TRPA1. Thus, ABT-102 shows greater than 3000-fold selectivity for the TRPV1 receptor over the other TRP receptors evaluated.
To further determine the specificity of ABT-102 for the TRPV1 receptor, the compound was profiled in a large panel of in vitro binding assays (Cerep, Poitiers, France). The assays included ion channels, G-protein coupled receptors, other receptors, and transporters (listed in Supplemental Table 1 ). ABT-102 showed little or no activity at all receptors, ion channels, and transporters evaluated (Supplemental Table 1). In additional, in-house assays, ABT-102 produced only 0 to 18% inhibition (at 3-100 M) of ligand binding to adrenergic, cannabinoid, dopamine, histamine, or nicotinic receptors or to the ␣2␦1 subunit of voltage-gated calcium channels. In Ca 2ϩ influx assays, ABT-102 (up to 100 M) did not block activation of P2X 7 receptors or N-methyl-D-aspartate NR1/ NR2B receptors. ABT-102 was also inactive (at 1-3 M) at human fatty acid amide hydrolase and at tetrodotoxin-resistant voltage-gated sodium channel currents in rat DRG neurons (data not shown). These data support the highly selective nature of ABT-102 for TRPV1.
ABT-102 Is a Competitive Antagonist at the CapsaicinBinding Site of the TRPV1 Receptor. To determine the nature of ABT-102 antagonism at the TRPV1 receptor, capsaicin concentration-effect curves were generated in the presence of increasing concentrations of ABT-102 using the HEK 293-based stable cell line expressing recombinant human TRPV1. As shown in Fig. 6A , capsaicin concentration-effect curves were shifted to the right with increasing concentrations of ABT-102, without affecting the maximal response for capsaicin. These results indicate that ABT-102 acts as a competitive antagonist at the TRPV1 receptor capsaicin-binding site. A Schild plot analysis yielded a pA 2 of 8.344 and a slope factor of 1.07 Ϯ 0.18 (Fig. 6B) .
ABT-102 Potently Blocks Activation of the Sensitized TRPV1 Receptor by Various Agonists. To determine the potency of ABT-102 under conditions where the TRPV1 receptor is sensitized before the addition of agonist, the receptor was sensitized through activation of PKC because this seems to be a common mechanism through which various agents sensitize TRPV1 (Bonnington and McNaughton, 2003; Moriyama et al., 2005; Sikand and Premkumar, 2007) . The recombinant human TRPV1 receptor was sensitized with a concentration (100 nM) of the PKC activator PDBu, which does not by itself activate TRPV1, as previously demonstrated (El Kouhen et al., 2005) . The pEC 50 values for capsaicin and NADA were 7.99 Ϯ 0.04 (EC 50 ϭ 10 nM) and 6.08 Ϯ 0.03 (EC 50 ϭ 0.83 M), respectively (Fig. 7A) . Compared with basal conditions (Supplemental Fig. 1A) , PKCmediated sensitization of recombinant human TRPV1 enhanced the potency of capsaicin and NADA by approximately 4-fold. A concentration of each agonist that corresponded to approximately its EC 50 value at the PKC-sensitized receptor, 10 nM for capsaicin and 0.8 M for NADA, was used to assess the potency of ABT-102. ABT-102 blocked activation of the PKC-sensitized receptor with similar potency to that at the naive receptor, with average pIC 50 values for capsaicin (Fig.  7B ) of 8.40 Ϯ 0.09 (IC 50 ϭ 4 nM; n ϭ 6) and for NADA (Fig.  7C ) of 8.41 Ϯ 0.08 (4 nM; n ϭ 6) at the sensitized receptor. ABT-102 also blocked heat activation of the PKC-sensitized receptor (Fig. 7D) , with a similar average pIC 50 value of 8.32 Ϯ 0.03 (IC 50 ϭ 5 nM; n ϭ 9).
ABT-102 Potently Blocks TRPV1 Activation-Induced CGRP Release from Rat DRG Neurons. The effect of ABT-102 on CGRP release by cultured rat DRG neurons was evaluated to determine whether ABT-102 blocked TRPV1-mediated downstream events. CGRP release in response to TRPV1 activation has been demonstrated previously (Tognetto et al., 2001 ). Capsaicin induced a dose-dependent increase in release of CGRP from rat DRG neurons (Supple- 
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at ASPET Journals on April 3, 2017 jpet.aspetjournals.org mental Fig. 2A) , with a pEC 50 value of 7.28 Ϯ 0.10 (EC 50 ϭ 52 nM). ABT-102 potently inhibited capsaicin-induced CGRP release, with a pIC 50 value of 7.24 Ϯ 0.11 (IC 50 ϭ 57 nM; n ϭ 8) (Supplemental Fig. 2B ).
ABT-102 Potently Blocks Heat-Evoked Activity of Spinal WDR and NS Neurons through an Inhibition of Peripheral TRPV1 Receptors. The effects of ABT-102 on neuronal excitability in vivo were evaluated in anesthetized rats. Discharge activity was recorded from 56 WDR and 22 NS neurons (891.8 Ϯ 144.3 m from the surface of the spinal cord) in CFA-inflamed and uninjured rats (n ϭ 5-9 per treatment group). In CFA rats, administration of ABT-102 (30 -300 nmol) into the neuronal receptive field dose-dependently reduced heat-evoked firing of WDR neurons compared with baseline levels (p Ͻ 0.05; Fig. 8, A and C) . The greatest reduction (69.5 Ϯ 6.7%) in thermally evoked WDR firing occurred 35 min after the injection of 300 nmol ABT-102 (Fig.  8C) . Likewise, 300 nmol ABT-102 also reduced the responses of NS neurons to noxious thermal stimulation in CFA-inflamed rats (p Ͻ 0.05, Fig. 8B ), with an observed maximal effect of 71.1 Ϯ 8.4% 35 min after injection. Injections of ABT-102 (300 nmol) into the contralateral noninflamed hind paw did not alter heat-evoked neuronal firing (data not shown).
In uninjured rats, injections of ABT-102 (300 nmol) into the ipsilateral hind paw also significantly reduced (p Ͻ 0.05) the thermally evoked discharges of both WDR (38.6 Ϯ 7.8%) and NS neurons (33.2 Ϯ 9.1%). However, the effects of ABT-102 in uninjured rats were significantly less than those observed in CFA-inflamed rats (Fig. 8D) .
Discussion
The present study characterizes functional and pharmacological properties of ABT-102, a structurally novel TRPV1 receptor antagonist. ABT-102 is a potent antagonist of multiple modes of TRPV1 activation. ABT-102 blocks capsaicininduced activation of recombinant human and rat TRPV1 receptors, as well as native rat TRPV1 receptors, with similar potency. ABT-102 also shows equivalent potency at human TRPV1 receptors activated by protons or by the putative endogenous ligands NADA and anandamide and at the PKCsensitized and activated human TRPV1 receptor. In addition, ABT-102 potently blocks heat-activated TRPV1 receptor currents. ABT-102 is a competitive and reversible antagonist of capsaicin-activated TRPV1 receptors and shows greater potency versus capsaicin-induced activation than several other reported TRPV1 receptor antagonists. ABT-102 is highly selective for TRPV1 over other TRP receptors and is also highly selective versus other receptors, ion channels, and transporters. ABT-102 potently blocks functional consequences of TRPV1 activation, including capsaicin-mediated CGRP release from DRG neurons in vitro and heat-evoked neuronal firing of WDR and NS spinal cord neurons after intraplantar administration in vivo.
The ability of ABT-102 to antagonize capsaicin-and proton-mediated TRPV1 receptor activation with equal potency places ABT-102 into a group with a limited number of other TRPV1 receptor antagonists, A-425619 (El Kouhen et al., 2005) , AMG 517 (Doherty et al., 2007) , and AMG 6880 (Gavva et al., 2005a) . In contrast, other reported TRPV1 antagonists effectively block capsaicin-induced TRPV1 recep- Shaded region on the paw represents the neuronal receptive field; n ϭ 5-9 per group, ‫,ء‬ p Ͻ 0.05 versus baseline evoked activity; ϩ, p Ͻ 0.05; ϩϩ, p Ͻ 0.01 versus vehicle-treated group. D, injection of ABT-102 (300 nmol in 50 l) also decreased the thermally evoked responses of WDR and NS neurons in uninjured rats, but these effects were significantly less than those observed in CFA-inflamed rats; n ϭ 5-6 per group. ‫,ء‬ p Ͻ 0.05 versus baseline evoked activity; ϩ, p Ͻ 0.05, versus uninjured group. tor activation but either have no effect on proton-induced activation (Gavva et al., 2005a) or show reduced potency for proton-versus capsaicin-induced TRPV1 activation (Gavva et al., 2005b; Gunthorpe et al., 2007) . Capsaicin binding and proton binding sites have been mapped to different regions of the TRPV1 receptor (Jordt et al., 2000; Gavva et al., 2004 Gavva et al., , 2005a . Thus, the equal potency of ABT-102 to block capsaicin-and proton-induced TRPV1 receptor activation suggests an ability to bind TRPV1 in a manner that prevents activation, irrespective of the distinct binding sites for capsaicin and protons. Gavva et al. (2005a) proposed that TRPV antagonists with similar potency to block activation by capsaicin and protons might lock the channel in a closed state, thus preventing activation by either agent. ABT-102 showed a somewhat slower rate of block of proton-activated currents compared with block of capsaicin-activated currents (Fig. 2) . It is possible that the different kinetics may be due to indirect block of proton-activated currents caused by binding of ABT-102 to the capsaicin-binding site. In this study, our aim was to determine potency of ABT-102 under conditions where the TRPV1 receptor was activated by several different stimuli. In future studies, it may be of interest to investigate, using more detailed kinetic analyses, the mechanism(s) involved in receptor antagonism.
The ability of TRPV1 receptors to be activated by diverse stimuli (Caterina et al., 1997; Smart et al., 2000; Huang et al., 2002; Cortright and Szallasi, 2004) highlights not only a key role for TRPV1 as a pain sensor but also the challenge of identifying potent antagonists that can effectively block many or all of the mechanisms of TRPV1 activation relevant to chronic pain. Moreover, TRPV1 sensitization and/or upregulation in response to inflammatory mediators, PKC, and growth factors (Sikand and Premkumar, 2007) add a further layer of complexity to targeting this receptor. Several selective TRPV1 receptor antagonists that block polymodal receptor activation show good efficacy in preclinical animal models of pain (Szallasi et al., 2007) . Likewise, ABT-102 is a potent blocker of these stimulus modalities both in vitro (this study) and in vivo (P. Honore, P. Chandran, G. Hernandez, D. M. Gauvin, J. P. Mikusa, C. Zhong, J. R. Ghilardi, M. A. Sevcik, R. M. Fryer, J. A. Segreti et al., unpublished data) . A hallmark of inflammation and associated pain is a decreased pH (to ϳpH 6.1-5.4) at the site of inflammation (Steen et al., 1992) and TRPV1 receptors expressed on nociceptors have been implicated in acid-mediated pain (Leffler et al., 2006) . Moreover, anandamide and NADA may play an enhanced role in evoked and spontaneous pain under sensitized pathological conditions (Premkumar et al., 2004; Singh Tahim et al., 2005; Huang and Walker, 2006) . Thus, the ability of ABT-102 to inhibit multiple modes of TRPV1 activation, including activation of the sensitized receptor, with the same high potency when assayed under equivalent conditions/levels of receptor activation, suggests a highly favorable pharmacological profile for this antagonist.
It is well known that CGRP plays a role in neurogenic inflammation and in central sensitization in pain (Kilo et al., 1997; Bird et al., 2006) and that TRPV1 receptor activation induces CGRP release from specific subsets of DRG neurons at central and peripheral terminals (Price and Flores, 2007) . ABT-102 shows potent and concentrationdependent block of TRPV1-mediated CGRP release from rat DRG neurons and clearly demonstrates the ability of ABT-102 to block a relevant downstream effect of TRPV1 activation that is strongly implicated in both central and peripheral aspects of pain.
Injection of ABT-102 into a rat hind paw decreased spinal cord WDR and NS neuronal responses to noxious thermal stimulation. These results confirm previous work from our laboratory and others that in vivo antagonism of TRPV1 receptors on peripheral terminals is sufficient to attenuate the transmission of noxious thermal signals to the spinal cord (Jhaveri et al., 2005; McGaraughty et al., 2006) . The effects of peripheral ABT-102 in both inflamed and uninjured rats suggests that TRPV1 has a thermal transduction role in both "normal" and pathological states. Nonetheless, ABT-102 had a greater effect in the CFA-inflamed rats than in the uninjured rats. This outcome is consistent with an injuryrelated up-regulation of TRPV1 receptors on peripheral terminals (Carlton and Coggeshall, 2001 ) and with the increased efficacy of intraplantar injected iodo-resiniferatoxin in the carrageenan model of acute inflammation compared with uninjured rats (Jhaveri et al., 2005) . In contrast, we had shown previously that intraplantar injection of another TRPV1 receptor antagonist, A-425619, was equally effective in inflamed and uninjured rats, despite a greater effect in inflamed rats after systemic and intra-DRG administration (McGaraughty et al., 2006) . Physiochemical properties of A-425619 may have contributed to the lack of differential action between inflamed and uninjured rats after intraplantar injection of this compound. The increased efficacy of ABT-102 (and iodo-resiniferatoxin) in models of inflammation is consistent with the amplified role of TRPV1 receptors after injury. The ability of intraplantar ABT-102 to block heatevoked WDR and NS neuronal firing in the dorsal horn of the spinal cord also underscores the important contribution made by the TRPV1 receptor in nociceptive pathways, its contributions to the summation of afferent inputs in the spinal cord (in addition to its expected sensitization of afferent nociceptive fibers), and its impact on central aspects of pain.
In summary, ABT-102 is a structurally novel TRPV1 receptor antagonist with overall superior potency and selectivity for TRPV1 receptors activated by multiple pain-related stimuli. It is noteworthy that ABT-102 also attenuates functional consequences of TRPV1 activation in pain pathways. The compound shows a favorable pharmacokinetic profile, oral bioavailability, and predicted good absorption in humans, as well as low in vitro metabolism (Gomtsyan et al., 2008) . ABT-102 shows analgesic efficacy in several rodent pain models (including chronic inflammatory, bone cancer, and postoperative pain) and an acceptable therapeutic index in preclinical studies (Gomtsyan et al., 2008) ment because it targets a key pain sensor that integrates multiple stimuli. The potential of this approach will be more fully revealed from clinical trials that have been initiated with several TRPV1 antagonists.
